High-throughput screening identification of USP7 inhibitors reveals YM155 as a biologically active scaffold with in vivo antitumor efficacy. (PubMed, Biomed Pharmacother) - Jul 29, 2026 - "Importantly, YM155 demonstrated significant tumor growth inhibition in lung and breast cancer mouse models, supporting its in vivo activity and pharmacological tractability in clinically relevant settings. Together, these findings expand the chemical space of USP7 inhibitors and identify YM155 as a hit for further optimization and mechanistic investigation toward USP7-targeted anticancer therapeutics."
Journal • Preclinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • FOXP3 • MYCN • PTEN • USP7
|
|
Ana S Leal; Caio Franco; David Eisenbarth; Jorge A R Salvador; Miguel Mano; Rahaf Habboub; Rita I Oliveira
|